Skip to main content
. 2022 Jun 22;30(11):3341–3357. doi: 10.1016/j.ymthe.2022.06.011

Figure 2.

Figure 2

The role of MECOM in prognosis of LUSC patients and CSC properties

(A) Representative images of MECOM expression in the tumor tissues of LUSC patients by immunohistochemistry. Scale bars, 50 μm.

(B and C) DFS (B) and OS (C) curves of 150 LUSC cases with different expression levels of MECOM.

(D and E) The representative photographs (D) and statistical efficiencies (E) of primary (1°) and secondary (2°) spheroids in H520 and EBC-1 cells with forced expression of MECOM (MECOM-OE). n = 6. Scale bars, 100 μm.

(F and G) The representative images (F) and percentages (G) of CD44 and CD133 in H520 and EBC-1 cells with forced expression of MECOM (MECOM-OE). n = 6.

(H and I) The representative photographs (H) and statistical efficiencies (I) of spheroids in SKMES-1 cells with depleted MECOM (sg-MECOM). Scramble sgRNA (Sg-scramble) was as the control. n = 6. Scale bars, 100 μm.

(J) Spheroid efficiencies in PDX tumor cells of LUSC006, LUSC018, and LUSC021 with depleted MECOM. n = 3. ∗p ＜ 0.05, unpaired 2-tailed t test in (E), (G), (I), and (J).